Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab

PloS one, 2024-02, Vol.19 (2), p.e0293264-e0293264 [Peer Reviewed Journal]

Copyright: © 2024 Heine et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ;COPYRIGHT 2024 Public Library of Science ;2024 Heine et al 2024 Heine et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0293264 ;PMID: 38300937

Full text available